MNG573
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.473
- MYC_TARGETS_V1+0.409
- E2F_TARGETS+0.354
- G2M_CHECKPOINT+0.347
- UV_RESPONSE_DN+0.337
- MITOTIC_SPINDLE+0.295
- TGF_BETA_SIGNALING+0.287
- MYC_TARGETS_V2+0.285
- UNFOLDED_PROTEIN_RESPONSE+0.268
- INTERFERON_ALPHA_RESPONSE+0.267
Top 10 suppressed
- CHOLESTEROL_HOMEOSTASIS-0.323
- IL6_JAK_STAT3_SIGNALING-0.307
- COAGULATION-0.306
- ALLOGRAFT_REJECTION-0.297
- TNFA_SIGNALING_VIA_NFKB-0.290
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.281
- P53_PATHWAY-0.278
- HYPOXIA-0.273
- MYOGENESIS-0.267
- XENOBIOTIC_METABOLISM-0.238
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934933 | — | — | 0.875 |
| 2 | SJEPD031236_D1.RNA-Seq | EPN | Supratentorial EPN | 0.841 |
| 3 | SRR934721 | — | — | 0.837 |
| 4 | 61F5C72A-4DDB-4EDB-908A-B2856CAFD8BD | — | — | 0.835 |
| 5 | 961CEC20-67F2-4615-8725-F35C12F0BC9B | — | — | 0.830 |
| 6 | SRR934847 | — | — | 0.825 |
| 7 | SRR934880 | — | — | 0.817 |
| 8 | SRR934823 | — | — | 0.817 |
| 9 | EED16435-CBED-4143-B5BA-C5C7C8510C3A | — | — | 0.816 |
| 10 | SRR934805 | — | — | 0.814 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.473 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.409 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.354 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.347 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.337 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.295 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.287 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.285 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.268 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.267 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.242 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.134 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.125 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.092 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.084 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.065 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.062 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.052 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.040 | Inavolisib | — uncovered |